Issue link: https://beckershealthcare.uberflip.com/i/1013189
17 Executive Briefing While length of stay is an important metric when choosing a treatment option, the likelihood for an inpatient to be discharged to home is equally important. Chen et al. reported BKP patients had a greater percentage of patients discharged home than the non-surgical management group. 6 Nearly 60 percent of the BKP patients were discharged to home, compared with 23.3 percent of the non- surgical management patients. The same observation was reported at Ong et al., where 56.9 percent of BKP patients were discharged to home, compared with 33.7 percent of the non- surgical management patients. 8 and at Zampini et al where 38.4% of BKP patients were discharged to home, compared with 21 percent of the non-surgical management patient. 7 Throughout his 20-plus years in practice, Dr. Hirsch has performed hundreds of vertebroplasties and kyphoplasties, seeing how his patients' lives change after undergoing the procedure. "People who weren't able to walk are dancing at their child's wedding," he said. "They are tending to their gardens and working in the chicken coop. There is no group of procedures more gratifying than vertebral augmentation." What's next for vertebroplasty and balloon kyphoplasty? Medtronic and NOF are strengthening their efforts to target healthcare providers as well as women age 50 and older — the most likely demographic to develop VCF — and educate them about treatment options. "Healthy women between the age of 50 and 65 years old diagnosed for the first time with osteoporosis don't necessarily feel sick; they aren't in pain," said Ms. Thompson. "But they do want to find resources and support, a community of people who can help them, and they aren't only interested in their own health, but the health of their family. Women are providing care for themselves, their partner or spouse and aging parents. We are educating this army in addition to family practice and local community members to provide a dynamic bone health world." Through their evidence-based partnership, NOF and Medtronic are developing educational materials, webinars and presentations for the medical professional and patient audience. Balloon kyphoplasty contributes to Medtronic's overall mission of developing therapies that can transform the lives of millions of people every day. "We invest heavily in new product innovation and build a strong level of clinical evidence to support our groundbreaking solutions," said Mr. Cambra. "Our mission is to alleviate pain and improve the quality of life for people with VCF." References 1 Tillman J, Shabe P, Rose M, Elson P, Wülfert E, Ashraf T. Fracture Reduction Evaluation Study 24-month final clinical study report, August 27, 2010. Medtronic Spinal and Biologics Europe BVBA 2. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non- surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):225-35. 3. Boonen S, Van Meirhaeghe J, Bastian L, et al. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res. 2011;26(7):1627-1637. 4. Van Meirhaeghe J, Bastian L, Boonen S, et al. A randomized trial of balloon kyphoplasty and nonsurgical management for treating acute vertebral compression fractures: vertebral body kyphosis correction and surgical parameters. Spine. 2013;38(12),971-983. 5. Becker S, Pfeiffer KP, Ogon M. Comparison of inpatient treatment costs after balloon kyphoplasty and non-surgical treatment of vertebral compression fractures. Eur Spine J. 2011; 20(8): 1259-1264. 6. Chen AT, Cohen DB, Skolasky RL. Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2013;95(19): 1729-1736. 7. Zampini JM, White AP, McGuire KJ. Comparison of 5766 vertebral compression fractures treated with or without kyphoplasty. Clin Orthop Relat Res. 2010;468(7):1773-1780. 8. Ong KL, Beall DP, Frohbergh M, et al. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty "sham" trials? Osteoporos Int. 2017 Oct 24. doi: 10.1007/s00198-017- 4281-z. PMD021217-2.0 / UC201901276 EN Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Jeff Cambra VP and General Manager RTG, Interventional Pain Medtronic